INSIGHTi
COVID-19 Vaccination: Selected U.S. Data
Sources
Updated April 11, 2022
The sources below can help congressional staff track the progress of the U.S. Coronavirus Disease 2019
(COVID-19) vaccination campaign at the national, state, and local levels.
Sources were selected for having commonly cited and frequently requested data. This list is not intended
to be comprehensive. Because different resources use different methodologies, readers should check
websites’ notes and caveats, and use caution when comparing data. For help interpreting or analyzing
these data, congressional staff should contact CRS (202-707-5700, or place an online request).
For an overview of considerations for Congress, see CRS Report R47024, Immunization Information
Systems: Overview and Current Issues and CRS Insight IN11584, Tracking COVID-19 Vaccines: U.S.
Data Systems and Related Issues. For international sources, see CRS Insight IN11732, International
COVID-19 Data and Vaccine Distribution: Selected Resources.
Centers for Disease Control and Prevention’s (CDC’s) Vaccines for COVID-19 can assist constituents
with questions about the vaccines.
Example sources on public attitudes toward vaccination include CDC’s National Immunization Survey,
COVIDVaxView, and State of Vaccine Confidence Insights Report, Kaiser Family Foundation, Carnegie
Mellon University, Johns Hopkins, and scholarly articles.
Vaccines.gov maps vaccination sites. Vaccine Equity Planner (Ariadne Labs) helps identify “vaccine
deserts” that lack convenient access to vaccination.
About Vaccine Data
In the COVID-19 vaccine program, jurisdictions (e.g., states, territories, tribes, and local entities), federal
agencies, and pharmacy partners determine the number and types of doses to be shipped to vaccination
sites. Doses are then delivered (i.e., distributed) to vaccination administration sites such as vaccination
clinics, doctors’ offices, and pharmacies. Providers then administer doses to patients and report
administration data to jurisdictions and CDC. (See CDC’s About COVID-19 Vaccine Delivered and
Administration Data.) Federal health care programs (e.g., Veterans Health Administration) manage
vaccine data through a similar process.
Congressional Research Service
https://crsreports.congress.gov
IN11595
CRS INSIGHT
Prepared for Members and
Committees of Congress
link to page 2 Congressional Research Service
2
FDA has approved or authorized three vaccines for the prevention of COVID-19 in different age groups,
summarized in Table 1.
Table 1. COVID-19 Vaccines Approved or Authorized by FDA
(as of April 11, 2022)
Pfizer-BioNTech
Moderna
J&J/Janssen
Primary Series
Two doses given three weeks
Two doses given four weeks
One dose
apart
apart
FDA Approval /
Yes, approved under the name
Yes, approved under the name
Not approved
Licensure
Comirnaty as a two-dose
Spikevax as a two-dose
regimen for individuals 16+
regimen for individuals 18+
Emergency Use
Yes, authorized as a
Yes, authorized as a
Yes, authorized as a
Authorization
two-dose regimen in
two-dose regimen for
single-dose regimen in
(EUA)
individuals 5+ (with a
ages 18+,
individuals 18+, and
lower dose authorized for third dose for certain
single booster dose to be
children 5-11),
immunocompromised
given at least two months
third dose for certain
individuals 18+,
after first dose in
immunocompromised
individuals 18+.
single booster dose (half
individuals 5+,
dose) to be given at least
single booster dose to be
five months after the
given at least five months
primary series in
after the primary series in
individuals 18+, and
individuals 12+, and
second booster dose to
second booster dose to
be given at least four
be given at least four
months after first booster
months after first booster
dose in individuals 50+
dose in individuals 50+
and in certain
and in certain
immunocompromised
immunocompromised
individuals 18+.
individuals 12+.
Source: Agata Bodie, Analyst in Health Policy, CRS, based on FDA’s documents at COVID-19 Vaccines.
Any of the available vaccines can be used as a “mix and match” booster dose in eligible individuals. CDC
recommends the Pfizer-BioNTech or Moderna vaccines to be given as a booster shot two months after
receiving the J&J/Janssen vaccine or five months after completing the Pfizer-BioNTech or Moderna
vaccination series. Additionally, CDC recommends that adults who received J&J/Janssen as both their
primary vaccine and booster dose at least four months ago may receive a second booster dose using the
Pfizer-BioNTech or Moderna vaccines.
CDC Sources
CDC provides data on doses and people vaccinated. Some aggregated national data are available for
federal entities (Bureau of Prisons, Department of Defense, Indian Health Service, and Veterans Health
Administration; see “Data Table”). CDC also tracks rates of COVID-19 cases, deaths, and
hospitalizations by vaccination and booster status. CDC continues to study vaccine effectiveness in real-
world conditions.
CDC (click map) compiles links to state dashboards, which may also track local data.
link to page 3 link to page 5 Congressional Research Service
3
Non-CDC Sources
Non-CDC sources provide different visualizations and analyses of CDC data and incorporate data from
various jurisdiction-specific sources:
Bloomberg
Covid Act Now (and Harvard analysis with congressional district estimates as of
September 2021)
Johns Hopkins University & Medicine (JHU)
Kaiser Family Foundation (KFF)
Washington Post (WP)
Centers for Medicare & Medicaid Services (CMS) posts nursing home-reported data.
Vaccination Data Sources
Table 2 links to websites containing specific vaccination statistics.
Table 2. Vaccination Data
(links to selected resources)
Measure
National
State
Local
Doses delivered
Number
CDC
CDC
—
Per capita
CDC download Data
CDC
—
Table)
By vaccine type (J&J/Janssen,
CDC
CDC (download Data Table) —
Spikevax/Moderna, Comirnaty/Pfizer-
BioNTech)
Doses administered
Number
CDC (also trend)
CDC (also trend)
Harvard (congressional
JHU
JHU
district)a
Per capita
CDC (download Data CDC
—
Table)
Bloomberg (also trend)
Bloomberg (also
trend)
Per day (daily count and 7-day
CDCb
CDCb
—
average, trend)
WP
WP
By vaccine type
CDC
CDC (download Data Table) —
Percentage of delivered doses that
Bloomberg (“Supply
Bloomberg (“Supply used”)
—
have been administered
used”)
Booster doses administered in last 7
CDCc
CDCc
days
link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 link to page 5 Congressional Research Service
4
Measure
National
State
Local
People vaccinated
People who received ≥1 dose
CDC (also trend)b
CDC (also trend)b
CDC (county)
(number)
CDC (CBSA)d
Harvard (congressional
district)a
People who received ≥1 dose
CDC
CDC
CDC (county)
(percentage)
Covid Act Now
Covid Act Nowe
CDC (CBSA)d
Covid Act Now (county,
metro area)e
Harvard (congressional
district)a
People ful y vaccinatedf (number)
CDC (also trend)b
CDC (also trend)b
CDC (county)
JHU
JHU
CDC (CBSA)d
WP
WP
Harvard (congressional
district)a
People ful y vaccinatedf (percentage)
CDC
CDC
CDC (county, also case
JHU
Covid Act Nowe
rates and testing positivity
WP
JHU
map)
WP
CDC (CBSA)d
Covid Act Now (county,
metro area)e
Harvard (congressional
district)a
WP (county)
People ful y vaccinatedf by vaccine
CDC
CDC (download Data Table) —
type
People who received additional
CDCg (also trendh)
CDC (download Data
CDC (county)
(including booster) doses
WP
Tableg) (also trendh)
CDC (CBSA)d
Covid Act Nowe
Covid Act Now (county,
WP
metro area)e
People eligible for booster who have
CDC (“First booster
—
—
not yet received it
eligibility”)
link to page 5 link to page 5 Congressional Research Service
5
Measure
National
State
Local
Demographicsi
CDC (race/ethnicity,
CDC (sex, age, trends)
CDC (age, county and
sex, age; also trends)
CDC (aged 65+)
CBSA)d
CDC (booster uptake CDCc (age)
CDC (aged 65+, county)
by race/ethnicity)
CDCj (urban/rural, trend)
CDC (social vulnerability,
CDC (aged 65+)
KFF (race/ethnicity)
urban/rural, county)
CDC (trends by age,
alongside cases)
CDC (disability status
and age,
race/ethnicity)
CDC (pregnant
people by
race/ethnicity, trend)
CDCj (urban/rural,
trend)
KFF (race/ethnicity)
WP (race/ethnicity,
age trends)
Nursing homes
Percentage of residents and staff
CDC (trend)
CDC (trend)
CMS (facility-level data in
vaccinated
CMS
CMS
“Search for a nursing
home”)
Medicare.gov (facility-level
data)
Source: CRS based on sources as of April 11, 2022.
Notes: Some sources report similar data, but with different visualizations and analysis.
a. Data were last updated September 2021 but may be of historical interest.
b. See also 7-day average trend alongside cases or deaths, see “View (right axis).”
c. Scrol to Excel spreadsheets under “Attachments.”
d. Scrol to Excel spreadsheets under “Attachments.” Metropolitan and Micropolitan Statistical Areas are col ectively
known as Core-Based Statistical Areas (CBSAs).
e. Search state, city, or county, then scrol to “% Vaccinated” for trend.
f.
As defined in these data sources, “ful y vaccinated” people have received the second dose of a two-dose vaccine or
one dose of a single-shot vaccine (CDC).
g. Includes number, percentage, and by vaccine type.
h. Select “People Receiving a Booster Dose” or “Vaccination Coverage.”
i.
Not all states report demographics on vaccine recipients.
j.
View “Urbanicity Chart.”
Author Information
Ada S. Cornell
Angela Napili
Senior Research Librarian
Senior Research Librarian
Congressional Research Service
6
Disclaimer
This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff
to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of
Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of
information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role.
CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United
States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However,
as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the
permission of the copyright holder if you wish to copy or otherwise use copyrighted material.
IN11595 · VERSION 18 · UPDATED